How Biotech Investment and Advanced Manufacturing Are Powering the Global Cell & Gene Therapy Manufacturing Services Market to USD 76.20 Billion by 2035

The cell and gene therapy manufacturing services market was valued at $7.74 billion in 2024 and is projected to reach $76.20 billion by 2035, growing at a CAGR of 23.1% during the forecast period (2025-2035). The global cell and gene therapy manufacturing services market is experiencing rapid expansion as biopharmaceutical companies intensify investments in next-generation therapeutics. A surge in venture funding, strategic alliances between biotech innovators and contract development and manufacturing organizations (CDMOs), and increased deal activity are accelerating the translation of cell and gene therapies from research to commercialization. These dynamics are driving strong demand for specialized, scalable manufacturing services that can support complex biologics production.

Browse the full report description of “Cell and Gene Therapy Manufacturing Services Market Size, Share & Trends Analysis by Therapy (Cell Therapy, and Gene Therapy), by Scale (Pre-commercial/ R&D Scale Manufacturing, and Commercial Scale Manufacturing) by Indication (Oncology, Cardiovascular Diseases, Orthopedic Diseases, Infectious Diseases, Ophthalmology Diseases, and Others) and by End User (Pharmaceutical and Biotechnology Companies, and Academic and Research Institutes) Forecast Period (2025-2035)” of https://www.omrglobal.com/industry-reports/cell-and-gene-therapy-manufacturing-services-market

Advancements in manufacturing technologies—including automated closed systems, single-use bioprocessing, and viral vector production platforms—are improving process efficiency, consistency, and cost control. At the same time, supportive regulatory frameworks and accelerated approval pathways for advanced therapies are encouraging faster clinical progression and earlier commercialization, further boosting outsourcing demand for compliant and flexible manufacturing infrastructure.

Key Market Developments Shaping the Global Cell and Gene Therapy Manufacturing Services

• 2024: Increased capital investment in viral vector and cell therapy manufacturing facilities to address capacity constraints.
• 2024-2025: Adoption of automation, digital process controls, and modular facilities to improve scalability and reduce production timelines.
• 2025: Expansion of regulatory fast-track programs and conditional approvals, reinforcing demand for compliant CDMO partnerships and global manufacturing networks.

Capacity Expansion, Platform Innovation, and End-to-End Service Integration

Manufacturing service providers are rapidly expanding global production capacity, investing in state-of-the-art facilities, and enhancing quality systems to meet stringent regulatory requirements. Companies are also developing integrated, end-to-end service offerings—spanning process development, clinical manufacturing, and commercial-scale production—to support therapy developers across the full product lifecycle. Strategic partnerships and long-term manufacturing agreements are becoming increasingly common as sponsors seek reliable, scalable supply chains.

Market Accelerates with Innovation, Strategic Partnerships, and Expanded Capacity

• In 2025, Thermo Fisher Scientific Inc. unveiled an expanded cell and gene therapy contract manufacturing platform featuring advanced automation, scalable viral vector production, and integrated quality analytics designed to support accelerated clinical and commercial manufacturing for global biopharma companies.
• In 2024, Lonza Group AG completed the acquisition of a specialized viral vector production and cell therapy technologies provider, strengthening its end-to-end manufacturing services and expanding its capabilities in AAV and lentiviral vector supply chains.
• In 2025, Catalent, Inc. announced a strategic collaboration with a leading gene therapy developer to co-develop and optimize manufacturing processes, analytical methods, and regulatory pathways for next-generation gene therapy products.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Therapy
• Scale
• Indication
• End User

• Competitive Landscape – Catalent Inc., Charles River Laboratories, FUJIFILM Diosynth Biotechnologies, Lonza Group AG and Thermo Fisher Scientific.

 Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

 Global Cell and Gene Therapy Manufacturing Services Market Report Segment

By Therapy

• Cell Therapy
• Gene Therapy

By Scale

• Pre-commercial/ R&D Scale Manufacturing
• Commercial Scale Manufacturing

By Indication

• Oncology
• Cardiovascular Diseases
• Orthopedic Diseases
• Infectious Diseases
• Ophthalmology Diseases
• Others

By End User

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes

Global Cell and Gene Therapy Manufacturing Services Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

 To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/cell-and-gene-therapy-manufacturing-services-market